Skip to main content

Table 1 Characteristics of systemic sclerosis patients included in the study

From: Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis

 

French cohort (n = 1,022)

Italian cohort (n = 594)

Combined cohort (n = 1,616)

Age in years, mean ± SD

57.4 ± 13.9

48.8 ± 13.4

53.1 ± 13.6

Male gender, number

152

55

207

Disease duration in years, mean ± SD

13.1 ± 7.1

12.4 ± 8.7

12.75 ± 7.9

lcSSc, percentage

60

74.7

64.4

dcSSc, percentage

29.5

25.2

28

Lung fibrosis seen on CT, percentage

36.1

34.6

35.3

FVC <75%, percentage

14

16.1

14.6

Digital ulcers (ever occurred), percentage

33

44

36.6

ACA+, percentage

32.3

44.6

36.6

Anti-topo I+, percentage

23

32.6

26.3

Associated AID, percentage

15

14.6

15

  1. ACA, anti-centromere antibody; anti-topo I, anti-topoisomerase antibody; associated AID, at least one associated autoimmune disease; CT, computed tomography; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; lcSSc, limited cutaneous systemic sclerosis; SD, standard deviation.